Tolemy Bio, an AI-in-bio startup, raised a €1.54 million ($1.54m) pre-seed round, bringing total funding to €1.4 million, per an interview report. The company attributed investor interest to a pivot that turned earlier services into a software platform called Orbit, focused on converting biological data into formats usable by AI systems. The funding round capped a quieter fundraising period during which the founders stepped back from public outreach to strengthen customer evidence and manufacturing partnerships that support the product narrative. For the sector, the raise reflects continued appetite for data-access and data-standardization infrastructure—useful building blocks for larger biotech automation and discovery workflows.